相关实验视频

Updated: Sep 9, 2025

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Published on: February 5, 2020

在尼沃卢马布治疗黑色素瘤期间晚发的血管免疫细胞T淋巴瘤

Akihiro Miyashita^1,2, Taichi Murao^3,2, Yuji Shimura^2,4

¹Department of Internal Medicine, John A. Burns School of Medicine, University of Hawai'i, Honolulu, USA.

|September 2, 2025

概括

长期免疫检查点抑制剂 (ICI) 治疗虽然对癌症有效,但可能会增加晚期T细胞淋巴瘤的风险. 对于长期接受ICI治疗的患者来说,仔细监测至关重要.

科学领域:

癌症学
免疫学
医疗病例报告

背景情况:

免疫检查点抑制剂 (ICI) 增强T细胞的抗癌活性.
免疫相关的不良事件是ICI常见的.
长时间的T细胞激活引起了对二次T细胞恶性瘤的担忧.

研究的目的:

在接受长期ICI治疗的患者中报告一种罕见的晚期T细胞淋巴瘤.
强调在接受长期ICI治疗的患者中对T细胞淋巴瘤的警监测的重要性.

主要方法:

一个56岁的女性因转移性黑色素瘤而接受治疗的病例报告.
详细的临床病史和同时发生的血管免疫T细胞淋巴瘤和ICI相关的胆脉炎的诊断结果.

主要成果:

经过七年多的尼沃卢马布治疗,该患者出现了血管免疫性T细胞淋巴瘤和ICI相关的胆管炎.
这种情况说明了长期免疫检查点抑制的潜在晚发症.

结论:

长期免疫检查点抑制剂治疗可能与T细胞淋巴瘤的发展有关.
持续监测患者至关重要,以检测和管理晚出现的不良事件,包括T细胞恶性瘤.

关键词:

血管免疫性T细胞淋巴瘤胆管炎免疫检查点抑制剂与免疫相关的不良事件尼沃卢马布

更多相关视频

Author Spotlight: Advancing the Detection of Low-Frequency Mutations in Cancer Tissues

Author Spotlight: Advancing the Detection of Low-Frequency Mutations in Cancer Tissues

Published on: August 23, 2024

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.